BEGIN:VCALENDAR
VERSION:2.0
PRODID:https://murmitoyen.com/events/vanille/udem/
X-WR-TIMEZONE:America/Montreal
BEGIN:VEVENT
UID:69ddb60615d0b
DTSTAMP:20260413T233534
DTSTART:20151028T110000
SEQUENCE:0
TRANSP:OPAQUE
DTEND:20151028T123000
URL:https://murmitoyen.com/events/vanille/udem/detail/630237
LOCATION:Université de Montréal - Pavillon Roger-Gaudry\, 2900\, chemin d
 e la Tour\, Montréal\, QC\, Canada\, H3T 1J6
SUMMARY:Conférence d'Alessandro Boezio\, Ph.D. (Amgen)
DESCRIPTION:Titre : Discovery of AMG 337\, A Potent and Selective Inhibitor
  of c-Met with High Unbound Exposure and Robust\, Extended In Vivo Antitum
 or Activity. Endroit : Pavillon Roger-Gaudry\, salle G-815 à 11 h.Hôte :
  Professeure Hélène Lebel.
\nLa conférence sera prononcée (en anglais)
  par Dr. Alessandro Boezio\, scientifique principal à Amgen Inc. (Cambrid
 ge\, MA).
\nRésumé : The receptor tyrosine kinase c-Met and hepatocyte g
 rowth factor (HGF)\, its endogenous ligand\, are implicated in several cel
 lular processes relevant to cancer\, including cell proliferation\, cell m
 igration\, and invasive growth. Deregulation of the c-Met/HGF pathway can 
 lead to tumorigenesis and metastasis. Amplification of the MET gene\, the 
 overexpression of c-Met and/or HGF\, and constitutive activation conferred
  by sequence mutations are some of the mechanisms of deregulation that hav
 e been found in human cancers. The potential blockade of both ligand-depen
 dent and ligand-independent activity of c-Met by an ATP-competitive small 
 molecule inhibitor acting via the intracellular kinase domain is an appeal
 ing strategy for the treatment of cancer. We previously reported the disco
 very of potent\, orally active c-Met inhibitors\, however\, each series su
 ffers from its own unique liabilities. Efforts to improve upon these inhib
 itors led to the discovery of a series of c-Met inhibitors leading to AMG 
 337. This presentation will describe the design\, synthesis\, pharmacokine
 tics and in vivo efficacy of this class of compounds. AMG 337 is currently
  in Phase 2 clinical trials for the treatment of cancer.
\nInformation sup
 plémentaire sur la société AmgenAnnonce PDF de la conférence
END:VEVENT
BEGIN:VTIMEZONE
TZID:America/Montreal
X-LIC-LOCATION:America/Montreal
END:VTIMEZONE
END:VCALENDAR